SCHEMBL6090430

SCHEMBL6090430

CN(C)CCCOc1ccc(C2NC(=O)c3cccc4c3N2CCC4=O)cc1

nearest known ligand 0.42

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 1/20 0.42
ESR1 P03372 1/20 0.42
HRH3 Q9Y5N1 4/20 0.39
LSS P48449 1/20 0.37
CACNA1B Q00975 1/20 0.37
MAOB P27338 1/20 0.37
KDM4E B2RXH2 2/20 0.36
ALDH1A1 P00352 2/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
MAPK14 Q16539 1/20 0.35
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
LMNA P02545 1/20 0.35
USP2 O75604 1/20 0.35
GAA P10253 1/20 0.35
HSD17B10 Q99714 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6090872 0.87 PARP1 (0.39) PARP1ESR1HRH3LSSCACNA1B
SCHEMBL6093054 0.86 GPR174 (0.41) PARP1ESR1HRH3KDM4EALDH1A1
SCHEMBL6091436 0.83 PARP1 (0.40) PARP1ESR1HRH3LSSCACNA1B
SCHEMBL6091022 0.83 PARP1 (0.40) PARP1ESR1HRH3LSSCACNA1B
SCHEMBL6092226 0.82 TNKS2 (0.45) MAOBKDM4EALDH1A1SMN1; SMN2MEN1
SCHEMBL6090229 0.80 ALDH1A1 (0.41) PARP1KDM4EALDH1A1MEN1KMT2A
SCHEMBL6090852 0.79 TSHR (0.40) KDM4EALDH1A1MEN1KMT2AGAA
SCHEMBL6091124 0.79 ALDH1A1 (0.44) KDM4EALDH1A1SMN1; SMN2USP2GAA
SCHEMBL6089480 0.79 TNKS2 (0.42) MAOBKDM4EALDH1A1SMN1; SMN2MEN1
SCHEMBL6093050 0.78 TNKS2 (0.34) KDM4EALDH1A1USP2GAAHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060004028-A1 Novel PARP inhibitor MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2006-01-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060004028-A1 Novel PARP inhibitor PARP1, PARP2, PARP11 PARP1 1/4885ESR1 2745/4885HRH3 2623/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.